Erythroid Neoplasm — Trials

Erythroid Neoplasm — Trials · CancerIndex

Clinical trials

Registered studies

260 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 48
Recruiting: 25
Ph III recruiting: 7
Growth YoY: —
Industry share: 48%
Top sponsor: National Cancer Institute (NCI)
Termination share: 35.9%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (50)

clinicaltrialsPublishedShowing 1–4 of 4 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT04717414	An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions(INDEPENDENCE)	active not recruiting	Phase 3	313	CelgeneINDUSTRY	26	Jul 16, 2026	clinicaltrials
NCT05481151	A Study to Assess Efficacy, Safety, and Tolerability of P1101 in Adult Patients With PV	active not recruiting	Phase 3	111	PharmaEssentiaINDUSTRY	2